{"nctId":"NCT00824655","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children","startDateStruct":{"date":"2009-03"},"conditions":["Pneumococcal Vaccines"],"count":234,"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: 13vPnC"]},{"label":"Group 2","type":"EXPERIMENTAL","interventionNames":["Biological: 13vPnC"]}],"interventions":[{"name":"13vPnC","otherNames":[]},{"name":"13vPnC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy children previously immunized with 1 or 2 doses of Prevenar.\n* Group 1: Male or female subjects between the age of \\>=140 and \\<=196 days of age at time of enrollment.\n* Group 2: Male or female subjects between the age of \\>=336 and \\<=392 days of age at time of enrollment\n* Available for entire study period.\n\nExclusion Criteria:\n\n* Previous reaction or contra-indication to pneumococcal vaccine or vaccine related component.\n* Previous vaccination with licensed or investigational pneumococcal vaccine other than Prevenar.","healthyVolunteers":true,"sex":"ALL","minimumAge":"140 Days","maximumAge":"392 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibodies 1 Month After the Toddler Dose","description":"Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.27","spread":null},{"groupId":"OG001","value":"5.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","spread":null},{"groupId":"OG001","value":"8.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.50","spread":null},{"groupId":"OG001","value":"3.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.22","spread":null},{"groupId":"OG001","value":"9.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":null},{"groupId":"OG001","value":"3.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.70","spread":null},{"groupId":"OG001","value":"8.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.27","spread":null},{"groupId":"OG001","value":"4.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.65","spread":null},{"groupId":"OG001","value":"1.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"1.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.02","spread":null},{"groupId":"OG001","value":"1.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":null},{"groupId":"OG001","value":"2.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.86","spread":null},{"groupId":"OG001","value":"3.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.25","spread":null},{"groupId":"OG001","value":"13.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Serotype-specific IgG Antibody Greater Than or Equal To (≥) 0.35 Mcg/mL, 1 Month After the Infant Dose","description":"Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Serotype-Specific Pneumococcal IgG Antibodies Measured 1 Month After the Infant Dose","description":"Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. GMCs calculated using all participants with available data for the specified blood draw.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Serotype-Specific Pneumococcal IgG Antibodies Measured Before the Toddler Dose","description":"Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) presented. GMC (13vPnC) and corresponding 2-sided 95% CIs evaluated. GMCs calculated using all participants with available data for the specified blood draw.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":null},{"groupId":"OG001","value":"0.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null},{"groupId":"OG001","value":"0.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":null},{"groupId":"OG001","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null},{"groupId":"OG001","value":"2.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null},{"groupId":"OG001","value":"0.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":"0.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":null},{"groupId":"OG001","value":"0.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":null},{"groupId":"OG001","value":"0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null},{"groupId":"OG001","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":null},{"groupId":"OG001","value":"1.55","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (5 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may have been represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days of the Toddler Dose (12 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may have been represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"52.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"52.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"59.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"51.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"26.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-specified Systemic Events Within 7 Days of the Infant Dose (5 Months of Age)","description":"Systemic events (any fever ≥ 38 degrees Celsius \\[C\\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may have been represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-specified Systemic Events Within 7 Days of the Toddler Dose (12 Months of Age)","description":"Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may have been represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"32.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null},{"groupId":"OG001","value":"44.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":null},{"groupId":"OG001","value":"38.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":null},{"groupId":"OG001","value":"33.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":118},"commonTop":["Irritability","Redness (Any)","Tenderness (Any)","Swelling (Any)","Redness (Mild)"]}}}